title: Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
abstract: This article discusses the patent strategy underlying the world's best selling drug, AbbVie's Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. This article is the first part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics.
authors: Ulrich
authors: U
authors: Storz
mesh_terms: D000068879:Adalimumab / Q000191:economics* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000191:economics* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000191:economics / Q000276:immunology / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics / Q000276:immunology / Q000473:pathology; D059451:Biosimilar Pharmaceuticals / Q000191:economics / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000191:economics / Q000276:immunology / Q000473:pathology; D034462:Dissent and Disputes / Q000266:history / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015870:Gene Expression; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D018973:Intellectual Property; D010330:Patents as Topic / Q000941:ethics / Q000331:legislation & jurisprudence*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Adalimumab; Humira; biosimilars; dosage; formulation; patent